Shilpa Gupta, MD

Where You Are:

Shilpa Gupta, MD

Medical Oncology

 
 

BOARD CERTIFICATION:
          •  Internal Medicine - Medical Oncology

FELLOWSHIP:
          •  Thomas Jefferson University - Genitourinary Oncology
          •  Thomas Jefferson University - Hematology Oncology
          •  Medical College of Wisconsin - Hematology Oncology
          •  Georgetown University - Hematology Oncology
          •  Royal College of General Practitioners, UK - Emergency Medicine

RESIDENCY:
          •  University of Connecticut - Internal Medicine

MEDICAL SCHOOL:
          •  Lady Hardinge Medical College, New Delhi, India - MD

  • Gallaher J, Cook LM, Gupta S, Araujo A, Dhillon J, Park JY, Scott JG, Pow-Sang J, Basanta D, Lynch CC. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastas. 2014 Aug. Pubmedid: 25173680.

  • Agarwal G, Gupta S, Spiess PE. Novel targeted therapies for the treatment of penile cancer. Expert Opin Drug Discov. 2014 Aug;9(8):959-968. Pubmedid: 24896220.

  • Dolan DE, Gupta S. PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. Cancer Control. 2014 Jul;21(3):231-237. Pubmedid: 24955707.

  • Freilich JM, Spiess PE, Biagioli MC, Fernandez DC, Shi EJ, Hunt DC, Gupta S, Wilder RB. Lipiodol as a Fiducial Marker for Image-Guided Radiation Therapy for Bladder Cancer. Int Braz J Urol. 2014 May;40(2):190-197. Pubmedid: 24856485.

  • Baumgarten AS, Emtage JB, Wilder RB, Biagioli MC, Gupta S, Spiess PE. Intravesical lipiodol injection technique for image-guided radiation therapy for bladder cancer. Urology. 2014 Apr;83(4):946-950. Pubmedid: 24397940.

  • Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R. Kidney cancer, version 2.2014. J Natl Compr Canc Ne. 2014 Feb;12(2):175-182. Pubmedid: 24586079.

  • Mahipal A, Kothari N, Gupta S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 2014 Jan;21(1):74-79. Pubmedid: 24357745.

  • Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell carcinoma. Ther Adv Urol. 2013 Oct;5(5):223-232. Pubmedid: 24082917. Pmcid: PMC3763778.

  • Nevalainen MT, Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue PA, Gomella LG, Huszar D. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res. 2013 Oct;19(20):5658-5674. Pubmedid: 23942095.

  • Gupta S, Mahipal A. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control. 2013 Jul;20(3):200-210. Pubmedid: 23811704.

  • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw. 2012 Apr;10(4):502-535. Pubmedid: 22491049.

  • Gupta S, Fishman M. Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opin Pharmacother. 2011 Dec;12(18):2915-2922. Pubmedid: 22098229.

  • Gupta S, Carballido E, Fishman M. Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther. 2011 Nov;4:79-96. Pubmedid: 21792315. Pmcid: PMC3143908.

  • Gupta S, Gupta R, Singh S, Pant L. Solitary intrascrotal neurofibroma: A case diagnosed on aspiration cytology. Diagn Cytopathol. 2011 Nov;39(11):843-846. Pubmedid: 21994196.

  • Koptyra M, Gupta S, Talati P, Nevalainen MT. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell B. 2011 Oct;43(10):1417-1421. Pubmedid: 21704724. Pmcid: PMC3163765.

  • Mahipal A, Gupta S. Small-cell carcinoma of the gallbladder: report of a case and literature review. Gastrointest Cancer Res. 2011 Jul;4(4):135-136. Pubmedid: 22368737. Pmcid: PMC3283103.

  • Dua V, Gupta S, Singh C. Evaluation of the nasolabial angle in the Indian population. Contemp Clin Dent. 2010 Apr;1(2):79-82. Pubmedid: 22114388. Pmcid: PMC3220091.

  • Gupta S, Mahipal A. A case of acquired hemophilia associated with bullous pemphigoid. Am J Hematol. 2007 Jun;82(6):502. Pubmedid: 17301969.

  • Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. Pharmacotherapy. 2007 Apr;27(4):616-618. Pubmedid: 17381391.

  • Weinberg B, Gupta S, Thomas MJ, Stern H. Pott's puffy tumor: Sonographic diagnosis. J Clin Ultrasound. 2005;33(6):305-307. Pubmedid: 16134159.

Dr. Shilpa Gupta is a genitourinary oncologist at Moffitt Cancer Center and assistant professor in oncology and internal medicine at the University of South Florida's Morisani College of Medicine.

In addition to her patient care and teaching responsibilities, Dr. Gupta is researching novel targeted therapeutic agents for prostate, bladder and kidney cancer. She has been a presenter and invited speaker at numerous national and international conferences, including GU ASCO, AACR, Men's Health World Congress in France, and Annual World Cancer Congress in Beijing she discussed the role of novel therapeutics and preclinical models for personalized medicine in prostate cancer. She currently the principal investigator on various clinical trials offering novel treatments in genitourinary cancers.

Dr. Gupta attended medical school at the Lady Hardinge Medical College in New Delhi, India, where she ranked with honors in her graduating class, and engaged in various outreach programs like the National Pulse Polio Immunization Program.

After a fellowship in emergency medicine through the Royal College of General Practitioners in the UK, she pursued a Master's in Health Informatics at the University of Minnesota following which she completed an internal medicine residency at the University of Connecticut Health Center. Dr. Gupta then pursued advanced training in oncology through fellowships at Georgetown University, Medical College of Wisconsin and Thomas Jefferson University.  At Thomas Jefferson University, she further specialized in genito-urinary research fellowship.

She is a member of several committees at Moffitt Cancer Center, including scientific review committee, protocol monitoring committee and clinical pathway development committee.  She is also a member of the genitourinary committe of the SWOG and on the panel for the NCCN Guidelines for kidney and testicular cancers.

TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions